Michael D. Prados, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Michael D. Prados, MD

Professor, Department of Neurological Surgery, and Director of Translational Research in Neuro-Oncology, UCSF
Charles B. Wilson, MD, Endowed Chair in Neurological Surgery, UCSF

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

View on UCSF Profiles

Cancer Center Membership

Program Member » Neurologic Oncology» Pediatric Malignancies

Research Summary

I have been involved in clinical and translational research in early-phase clinical trials for both children and adults with CNS malignancies since 1985. I have served as Project Leader (the North American Brain Tumor Consortium) or co-Project Leader (the Adult Brain Tumor Consortium) for 20 years. I had been the institutional Principal Investigator of the UCSF Member Institution for the Pediatric Brain Tumor Consortium for many years. I currently am Project Leader of the Ivy Foundation Early Phase Clinical Trials Consortium (seven member institutions) and Project Leader for the Pacific Pediatric Neuro-Oncology Consortium (eleven member institutions). I previously was the Program Leader for the Neurological Oncology Program for the HDFCCC, and previously the Director of Translational Research in Neuro-Oncology. In addition, I am the Clinical co-Leader of the UCSF Brain Tumor SPORE grant, and co-leader of the Clinical and Statistical Core, Administrative Core, and Project 3 co-leader within that grant.

Education

Mississippi State University, Starkville, 1966-1969, Biology
University of New Orleans, BS, 1969-1970, Biology
LSU School of Medicine, MD, 1970-1974, Medicine
LSU Charity Hospital, New Orleans, LA, Internship, 1974-1975, Medicine
LSU Earl K Long Hospital, Baton Rouge, LA, Residency, 1975-1977, Internal Medicine


Professional Experience

  • 1977-1978
    Instructor, Department of Internal Medicine, LSU School of Medicine, New Orleans, LA
  • 1979-1982
    Assistant Professor, Department of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1980-1982
    Clinical Director, Medical Oncology, Dept. of Medicine, LSU School of Medicine, Earl K Long Hospital, Baton Rouge, LA
  • 1983-1984
    Pulmonary Fellowship (12 months), Tulane University School of Medicine, New Orleans, LA
  • 1984-1985
    Asst. Clinical Director, Dept. of Pulmonary Medicine, Touro Infirmary, New Orleans, LA
  • 1985-1987
    Clinical Instructor, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, University of California, San Francisco, CA
  • 1988-1991
    Asst. Clinical Prof., Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1988-1989
    Acting Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1989-2005
    Director, Neuro-Oncology Program, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco
  • 1991-1995
    Assoc. Clinical Professor, Chief, Neuro-Oncology Service, Brain Tumor Research Center & Dept. of Neurological Surgery, School of Medicine, University of California, San Francisco, CA
  • 1995-present
    Professor in Residence, Dept. of Neurological Surgery, University of California, San Francisco
  • 2001-present
    Charles B. Wilson Professor of Neurological Surgery, University of California, San Francisco
  • 2005 - present
    Director of the Translational Research Program in Neuro-Oncology, Brain Tumor Research Center, Dept. of Neurological Surgery, University of California, San Francisco

Selected Publications

  1. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, James CD, Mueller S, Haas-Kogan DA. Erratum to: Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):395.
    View on PubMed
  2. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200.
    View on PubMed
  3. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL, Telomere Group EC, Samani NJ, Wiencke JK, Wrensch MR. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015 Dec 4.
    View on PubMed
  4. Wen Q, Jalilian L, Lupo JM, Li Y, Roy R, Molinaro AM, Chang SM, Prados M, Butowski N, Clarke J, Nelson SJ. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec; 8(6):446-55.
    View on PubMed
  5. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64.
    View on PubMed
  6. Dasgupta T, Olow AK, Yang X, Hashizume R, Nicolaides TP, Tom M, Aoki Y, Berger MS, Weiss WA, Stalpers LJ, Prados M, David James C, Mueller S, Haas-Kogan DA. Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. J Neurooncol. 2016 Feb; 126(3):385-93.
    View on PubMed
  7. Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015 Sep 8; 6(26):21993-2005.
    View on PubMed
  8. Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY. Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors. J Clin Oncol. 2015 Oct 1; 33(28):3186-92.
    View on PubMed
  9. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53.
    View on PubMed
  10. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5.
    View on PubMed
  11. Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015 Aug 20; 33(24):2646-54.
    View on PubMed
  12. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015 Jun 25; 372(26):2499-508.
    View on PubMed
  13. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63.
    View on PubMed
  14. Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015 Jan; 121(2):331-9.
    View on PubMed
  15. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47.
    View on PubMed
  16. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40.
    View on PubMed
  17. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8.
    View on PubMed
  18. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2015 Mar; 17(3):440-7.
    View on PubMed
  19. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90.
    View on PubMed
  20. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel-Passow JE. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet. 2014 Jul; 46(7):731-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI